Clinical Trials Logo

Metastatic Mucosal Melanoma clinical trials

View clinical trials related to Metastatic Mucosal Melanoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03865212 Active, not recruiting - Metastatic Melanoma Clinical Trials

Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma

Start date: June 12, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of a modified virus called VSV-IFNbetaTYRP1 in treating patients with stage III-IV melanoma. The vesicular stomatitis virus (VSV) has been altered to include two extra genes: human interferon beta (hIFNbeta), which may protect normal healthy cells from becoming infected with the virus, and TYRP1, which is expressed mainly in melanocytes (specialized skin cell that produces the protective skin-darkening pigment melanin) and melanoma tumor cells, and may trigger a strong immune response to kill the melanoma tumor cells.

NCT ID: NCT03025256 Active, not recruiting - Metastatic Melanoma Clinical Trials

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

Start date: May 2, 2018
Phase: Phase 1
Study type: Interventional

This phase I/Ib trial studies the side effects and best dose of intrathecal nivolumab, and how well it works in combination with intravenous nivolumab in treating patients with leptomeningeal disease. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT02506153 Active, not recruiting - Clinical trials for Clinical Stage IV Cutaneous Melanoma AJCC v8

High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Start date: November 10, 2015
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies how well high-dose recombinant interferon alfa-2B or ipilimumab works compared with pembrolizumab in treating patients with stage III-IV melanoma that has been removed by surgery but is likely to come back or spread. High-dose recombinant interferon alfa-2B may help shrink or slow the growth of melanoma. Immunotherapy with monoclonal antibodies, such as ipilimumab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether high-dose recombinant interferon alfa-2B or ipilimumab is more effective than pembrolizumab in treating patients with melanoma.